Kura Oncology, Inc. KURA

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option P

Board additions bring diabetes-development and company-building expertise as Caspian prepares KO-7246 for advancement into clinical testingSAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”), a biotechnology company developing menin inhibitors for diabetes and other cardiometabolic diseases, today announced the appointments of Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to its Board of Directors. Caspian recently launched with $50 million in financing to advan

– KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models – – KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide – – Findings highlight a potentially disease-modifying approach designed to restore the body’s own endogenous insulin-producing capacity – – Caspian is building a leadership position in menin-direct

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leade

Kura Oncology stock has delivered a solid 55.5% return over the past year, yet on broad valuation checks it still screens as expensive rather than a clear bargain. For investors, that combination of strong recent gains and a low value score raises questions about how much good news is already reflected in the current share price. The 55.5% 1 year gain highlights how strongly sentiment has improved toward Kura Oncology, which can leave less room for disappointment if expectations...

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m. ET / 12:45 p.m. PT Cantor Global Healthcare ConferenceSeptember 9, 20269:10 a.m. ET / 6:10 a.m. PT Morgan Stanley Global Healthcare Conference September 16, 20267:45 a.m. ET / 4:45 a.m.

Shares of Kura Oncology hit a 52-week closing high after CEO Troy Wilson bought $1.2 million worth of stock.

According to a filing with the SEC, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24 for about $1.24 million in total.

Kura Oncology stock rallies as the CEO revealed another $1.24 million purchase of company shares. Wall Street continues to see massive further upside in KURA shares.

Kura Oncology Inc. (NASDAQ:KURA) shares climbed 11.